Filing Flows › RenovoRx (RNXT) › Q3 2025
RenovoRx (RNXT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
RenovoRx (RNXT) reported revenue of $266K for the third quarter 2025 (Q3 2025) and -37% from the quarter before.
RenovoRx, Q3 2025: revenue $266K, net loss $2.9M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $266K | -37% | — |
| Operating profit | −$3.2M | — | — |
| Net earnings | −$2.9M | — | — |
| Operating cash flow | −$2.3M | — | — |
What changed
Revenue was $266K in Q3 2025, down 37% from the previous quarter.
Gross margin was 80.1%. Operating costs exceeded revenue by $3.2M, an operating margin of -1203.0%. The quarter ended with a net loss of $2.9M, wider than the previous quarter's $2.9M loss.
Operating cash flow was −$2.3M. Non-cash charges added back $1.0M of depreciation and amortization and $349K of share-based compensation. Working capital and other items used $707K.
Questions
What was RenovoRx's revenue in the third quarter 2025?
RenovoRx (RNXT) reported revenue of $266K for the third quarter 2025 (Q3 2025) and -37% from the quarter before.
Source: RenovoRx 10-Q on SEC EDGAR.